Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryBCBS Tennessee MS Products Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_71362026_1126

    Multiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_71362026_1126 alerts

    Get alerted when Policy ID_CHS_71362026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Briumvi, Ocrevus, and Ocrevus Zunovo used to treat specified forms of multiple sclerosis and clinically isolated syndrome when stated approval criteria are met, subject to the member’s benefit plan and exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMultiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi
    Policy CodePolicy ID_CHS_71362026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionThe medication must be prescribed by or in consultation with a neurologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Products addressed
    12 monthsAuthorization period
    NeurologistRequired specialty
    Not allowedConcurrent MS disease-modifying therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medical Necessity and Authorization Criteria

    FDA-approved covered indications

    Coverage is available when the indication is FDA-approved or a compendial use, all approval criteria are met, and the member has no exclusions to the prescribed therapy.

    Covered product-specific indication

    • Briumvi indication: Member is an adult with a relapsing form of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.Adult
    • Ocrevus indication: Member has a covered Ocrevus indication: relapsing forms of multiple sclerosis in an adult; primary progressive multiple sclerosis in an adult; or relapsing-remitting multiple sclerosis in a pediatric patient age 10 years or older weighing 25 kg or more.Pediatric: age ≥10 years and weight ≥25 kg
    • Ocrevus Zunovo indication: Member is an adult with relapsing forms of multiple sclerosis or primary progressive multiple sclerosis.Adult

    Relapsing forms of multiple sclerosis

    Authorization of 12 months may be granted when the criterion below is met.

    Relapsing multiple sclerosis: Member has been diagnosed with a relapsing form of multiple sclerosis, including relapsing-remitting disease or secondary progressive disease for those who continue to experience relapse.Authorization period: 12 months

    Clinically isolated syndrome

    Authorization of 12 months may be granted when the criterion below is met.

    Clinically isolated syndrome: Member is receiving treatment for clinically isolated syndrome of multiple sclerosis.Authorization period: 12 months

    Primary progressive multiple sclerosis

    Authorization of 12 months may be granted when the criterion below is met.

    Primary progressive multiple sclerosis: Member is receiving Ocrevus or Ocrevus Zunovo for primary progressive multiple sclerosis.Authorization period: 12 months

    Continuation therapy

    For all indications, authorization of 12 months may be granted when the criterion below is met.

    Continuation response: Member, including a new member, achieves or maintains a positive clinical response while receiving the requested medication, evidenced by disease stability or improvement.Authorization period: 12 months

    Applies to all indications.

    Other criteria

    The following additional criteria apply.

    Additional criteria

    • No concomitant disease-modifying therapy: Member will not use the requested medication concomitantly with another disease-modifying multiple sclerosis agent.

      Ampyra and Nuedexta are not disease-modifying agents for this criterion.

    • Pediatric risk-benefit exception: For products FDA-approved in adults only, authorization may be granted to a pediatric member younger than 18 years when the benefits outweigh the risks.Age <18 years

    Off-Label Indications of FDA-Approved Drugs

    Off-label indications for FDA-approved drugs are recognized for coverage when supported by an authorized source.

    Recognized support for off-label use: The off-label indication is recognized in one of the statutorily recognized standard reference compendia or in published peer-reviewed medical literature.

    Applies to off-label indications of FDA-approved drugs under Tennessee Code Annotated Section 56-7-2352.

    Indications other than the listed indications for the applicable product are considered experimental/investigational and not medically necessary.

    Coverage is available only when the applicable approval criteria are met and the member has no exclusions to the prescribed therapy under the member’s benefit plan.

    For Ocrevus Zunovo, covered indications include treatment of relapsing forms of multiple sclerosis—including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease—in adults, and treatment of primary progressive multiple sclerosis in adults. All other indications are considered experimental/investigational and not medically necessary.

    Prior Authorization Submission Requirements

    Prior Authorization

    Obtain neurologist involvement

    The medication must be prescribed by or in consultation with a neurologist.

    Documentation Required

    Document a covered MS diagnosis

    Submit authorization for the applicable covered diagnosis: relapsing multiple sclerosis, clinically isolated syndrome, or primary progressive multiple sclerosis when requesting Ocrevus or Ocrevus Zunovo.

    Documentation Required

    Show positive response for continuation

    For continuation, demonstrate that the member has achieved or maintained a positive clinical response while receiving the requested medication, evidenced by disease stability or improvement.

    Prior Authorization

    Confirm no concurrent MS therapy

    Confirm that the requested medication will not be used concomitantly with another disease-modifying multiple sclerosis agent.

    Denial Risk

    Avoid unapproved indications

    Use for indications outside the listed FDA-approved indications for the requested product may result in noncoverage; such indications are considered experimental/investigational and not medically necessary.

    Denial Risk

    Apply the concomitant-therapy restriction

    The member must not use the requested medication concomitantly with another disease-modifying multiple sclerosis agent. Ampyra and Nuedexta are not considered disease-modifying agents for this restriction.

    Prior Authorization

    Ensure neurologist participation

    The medication must be prescribed by or in consultation with a neurologist.

    Denial Risk

    Prevent continuation denial for inadequate response

    Continuation authorization requires a positive clinical response while receiving the requested medication. Document disease stability or improvement; an insufficient response creates a continuation risk.

    Policy Scope and Therapeutic Context

    This policy addresses monoclonal antibody therapies used to treat specified forms of multiple sclerosis, including relapsing forms, clinically isolated syndrome, and primary progressive multiple sclerosis. Coverage for Briumvi, Ocrevus, and Ocrevus Zunovo is subject to the product-specific indication, applicable approval criteria, and member benefit exclusions.

    Key Clinical Terms

    Relapsing forms of multiple sclerosis
    Clinically isolated syndromeIncluded within relapsing forms of multiple sclerosis.
    Relapsing-remitting diseaseIncluded within relapsing forms of multiple sclerosis.
    Active secondary progressive diseaseIncluded within relapsing forms of multiple sclerosis.
    Disease-modifying multiple sclerosis agent
    Disease-modifying multiple sclerosis agentApplies to the concomitant therapy restriction for the requested medication.
    AmpyraNot considered a disease-modifying multiple sclerosis agent.
    NuedextaNot considered a disease-modifying multiple sclerosis agent.
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMultiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi
    Policy CodePolicy ID_CHS_71362026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionThe medication must be prescribed by or in consultation with a neurologist.
    SourceLink
    On This Page
    Medical Necessity and Authorization CriteriaPrior Authorization Submission RequirementsPolicy Scope and Therapeutic ContextKey Clinical Terms